Human tumor cell lines are powerful tools for investigating basic and applied aspects of cell biology. Leukemia-lymphoma cell lines have been instrumental in the cytogenetic and molecular analysis of recurring chromosome rearrangements, notably translocations and inversions, thus illuminating the pathogenesis of hematological malignancy. Chromosomal translocations targeting the MLL gene at 11q23 have come to represent a paradigm in acute leukemias. These translocations result in the in-frame joining of the MLL gene with a partner gene to generate unique fusion proteins of putatively novel function. More than 30 partner genes that participate with MLL in the more than 60 known 11q23 translocations have been reported. Cell lines provide territory to both explore the detailed structures of 11q23 translocations and investigate the leukemogenic activities of MLL fusion proteins. We review here the leukemia cell lines that have been described to carry 11q23 translocations and MLL fusion genes. Except for the t(10;11)(p12;q23), each of the following relatively frequent 11q23/MLL translocations is represented by one or more cell lines: 16 cell lines with t(4;11)(q21;q23), two cell lines with t(6;11)(q27;q23), seven cell lines with t(9;11)(p22;q23), and eight cell lines with t(11;19)(q23;p13). For each of three rare translocations, one cell line has been reported: t(5;11)(q15;q23), t(11;16)(q23;p13), and t(X;11)(q13;q23). Of these 36 cell lines with 11q23 translocations, 17 have been made available to us; we confirmed the occurrence of the alterations reported in these cell lines at the chromosomal and/ or gene level. A second type of MLL gene alteration is the partial tandem duplication (PTD), which occurs in acute myeloid leukemia (AML). We found four AML cell lines with an MLL PTD; one acute lymphoblastic leukemia-derived cell line was reported to show a partial nontandem duplication. Finally, a third rearrangement involves intrachromosomal amplification of the unrearranged MLL gene leading to multiple copies of the gene and (presumably) increased expression. Three cell lines carrying such MLL amplifications have been described. The availability of these cell lines as model systems provides the opportunity to explore the altered expression or functions of MLL genes and their partners in oncogenesis.
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Introduction
Cultured cell lines have become a unique resource, both in academic research and in industrial biotechnology. Key advantages of continuous cell lines are the unlimited supply and worldwide availability of identical cell material and their cryopreservability. Leukemia-lymphoma (LL) cell lines are characterized generally by monoclonal origin and differentiation arrest, sustained proliferation in vitro with preservation of most cellular features, and specific genetic alterations. 1 The continuous increase in their use over the last 2-3 decades has provided evidence of the enormous potential of LL cell lines.
Classical cytogenetics and molecular biology have benefitted greatly from the spectrum of available LL cell lines. The detailed analysis of recurrent chromosome rearrangements in LL cell lines has facilitated discovery of new oncogene rearrangements and of the resulting pathogenetic effects. Indeed, many cell lines have been instrumental in the cytogenetic detection of novel alterations and cloning of the genes involved (for a detailed review, see Drexler et al 
11q23 alterations
Several hundred recurring chromosomal translocations in leukemia-lymphoma have been described, 4 of which a large percentage has been analyzed at the molecular level. These translocations lead to the formation of fusion genes in many instances. One particular oncogene, MLL at 11q23, is blatantly promiscuous, pairing up with a large number of different partner genes. To date, over 60 chromosome partners of 11q23 have been described, and 33 of the presumptive gene partners of MLL cloned and analyzed at the molecular level (reviewed comprehensively in Huret 5 ; and JL Huret, August 2003, personal communication). The notion of ''fusion gene networks'' for the formation of fusion genes with a number of other partner genes (another prominent example is the gene ETV6/TEL) has recently been proposed. 6 Possible molecular mechanisms underlying leukemogenesis by MLL fusion proteins, including the question whether gains or losses of function are involved, have been discussed elsewhere. [7] [8] [9] [10] [11] [12] Recently, Milne et al 13 showed that MLL regulates HOX gene expression and provided addditonal data suggesting that MLL and MLL fusion proteins act to control target gene transcription by different mechanisms. Acute lymphoblastic leukemia (ALL) patients with MLL rearrangements have a dismal prognosis, displaying a distinct gene expression profile resembling an early hematopoietic progenitor expressing specific HOX genes and may be used to distinguish ALL with MLL rearrangements from remaining cases of ALL and acute myeloid leukemia (AML).
14 Based on these observations, these authors proposed a novel leukemic entity defined by MLL expression, and pinpointed genes selectively expressed therein as potential therapeutic targets.
A common problem for those investigating the classical or molecular cytogenetics of 11q23 anomalies is access to sufficient numbers of malignant cells or the unavailability of (nonrenewable) primary cells at different disease time points as patients may be cured or succumb. These limitations have given added impetus to the establishment of well-characterized LL cell lines with specific chromosomal alterations. Fortunately, a sizable corpus of cell lines carrying a wide range of the more common 11q23 alterations has been established. As these cell lines provide a useful platform for the study of these abnormalities, we have attempted to summarize and examine these cell lines in detail in this article.
11q23/MLL translocations
The various 11q23/MLL translocations may be conveniently divided into (i) frequent (each representing more than 5% of the cases) and (ii) rare incidences (less than 1%). The most frequent anomaly is the t(4;11)(q21;q23), leading to the fusion gene MLL- AF4 and representing about one-third of all 11q23 cases. 5, 15 It is found mainly (95%) in B-cell precursor (BCP) ALL, but also in AML, and predominantly in children. As expected, t(4;11) cell lines form the largest MLL category of all, their disease origins reflecting the clinical distribution: a total of 16, comprising both BCP (n ¼ 14) and monocytic (n ¼ 2), cell lines carrying the t(4;11) have been published (Table 1) . While the t(4;11) had been described for all these cell lines, the formation of the fusion gene had not been examined in all of these cell lines. We, therefore, sought to validate the translocations and the fusion genes in those MLL cell lines that were available to us as indicated in Table 1 (see also Figure 1 ).
The t(6;11)(q27;q23), which forms the fusion gene MLL-AF6, represents 5% of 11q23 cases, mainly AML M4 and AML M5, and is represented by two cell lines (Table 1 ). In total, seven cell lines, carrying the t(9;11)(p22;q23) with the MLL-AF9 fusion Indicates whether the original investigators have proven that the cell line was derived from the patient described, thus excluding crosscontamination and overgrowth by an already established cell line. For abbreviations see legend to Table 1. gene, have been published, both BCP (n ¼ 1) and monocytic (n ¼ 6) in origin. The t(9;11) has been reported to occur in 1/4 of 11q23 cases and is found predominantly in AML M4/M5 (80%) but rarely in ALL (10%). The location of the breakpoint on the short arm of chromosome 19 distinguishes the t(11;19)(q23;p13.1) with the fusion gene MLL-ELL from the t(11;19)(q23;p13.3) with the fusion gene MLL-ENL, each type representing about 5% of the 11q23 cases and occurs either in AML M4/M5 or in ALL (including T-ALL). However, distinguishing these microscopically very similar entities requires analysis at the molecular level (eg by reverse transcriptase-PCR or single-locus fluorescence in situ hybridization), but to date only one of the eight t(11;19) cell lines hitherto described, KOCL-33 with MLL-ENL, 24 has been so characterized. To our knowledge, there is no LL cell line carrying the relatively frequent (5%) t(10;11)(p12;q23) (fusion gene MLL-AF10), which is seen mainly in AML M4/M5.
Several dozen different MLL/11q23 partners comprise the list of rare 11q23 anomalies. 5 There are cell lines available for the following three of these rare abnormalities (Table 1) : KP-L-RY with a t(5;11)(q15;q23) and the MLL-AF5q31 fusion gene; SN-1 with a t(11;16)(q23;p13) and the MLL-CBP fusion gene; and Karpas 45 with a t(X;11)(q13;q23) and the MLL-AFX1 fusion gene.
MLL partial tandem duplications
The so-called partial tandem duplication (PTD) leads to fusion of the 5 0 portion of the MLL gene with itself. 48, 49 This abnormality is associated with AML, the incidence lying in the range of 3-10% of unselected cases 50, 51 but rises to 90% of AML cases with trisomy of chromosome 11.
48,49
Recently we screened a large panel of LL cell lines (74 AMLand 73 ALL-derived) for this mutation (32 and additional unreported results). While none of the ALL cell lines showed an MLL PTD, four positive AML cell lines were detected (Table 2 ). Interestingly, cell lines CTS and UG3 in addition carry the balanced MLL translocations t(6;11) and t(9;11), respectively. A partial nontandem duplication with the insertion of one AF9 exon has been reported for BCP-ALL cell line PER-377. 55 
MLL gene amplifications
Some 11q23 patients exhibit intrachromosomal amplification of unrearranged MLL, 56, 59, 60 presumably to facilitate increased MLL expression. In addition, three leukemia cell lines with such MLL amplifications have been described ( Table 2 ). The megakaryocytic cell line UoC-M1, established from a patient with AML M1, was shown to carry alternating segments of chromosomes 9 and 11 and four copies of the MLL gene against a near-diploid background. 57 Cell line SAML-2, derived from a patient with therapyinduced AML after radiation and chemotherapy for Hodgkin's disease, has two derivative chromosomes involving exchange and duplication of material between chromosomes 8 and 11, with amplification of MYC and MLL. 58 An MLL probe detected multiple signals on a der(5)t(5;11) chromosome and on a der(11) chromosome in cell line 2L1, which was established from a child with treatment-related AML postchemotherapy and radiation for neuroma and rhabdomyosarcoma. 56 However, the transcriptional consequences of genomic amplifications of MLL have yet to be investigated in these cell lines.
Conclusion
We discussed the range of available cell lines with a diversity of structural chromosome rearrangements covering the major types of MLL alteration. For all three types of MLL alteration discussed here, one or more continuous cell lines are available: (i) four frequent and three unfrequent variants of balanced 11q23 translocations with MLL-partner fusion genes, (ii) MLL partial tandem duplications, and (iii) MLL amplifications. Investigators interested in establishing new cell lines -no easy task (!) 61 - Figure 1 Cytogenetic analysis of MLL translocations. The images show the results of hybridizing metaphase chromosome preparations from the SEM cell line with t(4;11)(q21;q23) (a) and the NOMO-1 cell line with t(9;11)(p22;q23) (b) with a dual-color FISH probe comprising centromeric (red label) and telomeric (green label) large insert clones flanking the consensus breakpoint cluster region of MLL (Dako, Glostrup, Denmark). Such ''split-signal'' probes permit rapid unequivocal diagnosis of MLL rearrangements even in cryptic rearrangements. In both cases, the unrearranged N11 serves as an internal control for identifying the respective translocation partners. The insets show partial G-banded karyotypes of t(4;11) and t(9;11) in SEM and NOMO-1, respectively; the participant homologs are indicated by arrows. Note that while t(4;11) is relatively straightforward to identify because the rearranged chromosomes are grossly altered in size, the t(9;11) involves the exchange of visually similar chromosomal segments and is often quite difficult to identify. Thus, the der(ivative) and N(ormal) chromosomes 11 present in NOMO-1 (b) appear quite similar. Distinguishing the der(9) and its homolog in NOMO-1 depends on secondary rearrangements affecting these chromosomes, that is, deletion of 9p material affecting the der(9) and formation of t(9;13)(q13;q11) from the residual homolog.
might well now focus on culturing primary cells with MLL translocations for which no cell lines are available, for example, t(10;11)(p12;q23) together with more rare translocations.
The analysis of cell lines with mutated MLL will not only help us better understand this key disease gene and its pathogenetic effects but also to clarify the mechanisms by which altered genes or fusion oncogenes act in general, for example the role of transcribed reciprocal fusion genes. The ability to create specific disease models will also enable drug screening on proximate models of human disease rather than on animal surrogates. In short, to further our understanding of the role of MLL in disease, there has been no better time to exploit the resource afforded by cell lines harboring specific MLL gene alterations.
